Consequently, Liu et al. investigated the SALL4 methylation status in MDS patients treated with HMAs demonstrating reduced methylation at the relevant 5′-UTR CpG site in patients with elevated SALL4 expression after treatment with azacitidine or decitabine. Here, SALL4 is linked to myelodysplastic syndrome.